Home
Hanmi Pharm

Hanmi Pharm Market Share Analysis for June 2026

설명한미약품은 1973년 임성기 회장이 설립한 대한민국의 완제 의약품 제조업체이다. 본사는 서울특별시 송파구 방이동 몽촌토성역과 한성백제역 사이에 있으며, 본점은 경기도 화성시 팔탄면 하저리 팔탄공단에 있다. 위키백과

Health > Health - Other

Domainhanmi.co.kr

Year Founded1973

Employees1001 - 5000

Annual Revenue$5M - $10M

Hanmi Pharm

Hanmi Pharm (including company regionals)

hanmi.co.kr

See more website traffic and engagement information

Hanmi Pharm Revenue up to June 2026 is 5M - 10M

revenue generated by Hanmi Pharm top domains

Hanmi Pharm top domains revenue over 3 years

Revenue for Hanmi Pharm top domains

hanmi.co.kr5M - 10M

See more with Sales Intelligence

Total visits to Hanmi Pharm's top domains

Understand Hanmi Pharm market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

hanmi.co.kr65.2K

See more with Sales Intelligence

Avg. visit duration in Hanmi Pharm's top domains

Analyze Hanmi Pharm engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

hanmi.co.kr00:01:25

See more with Sales Intelligence

Avg. pageviews on Hanmi Pharm's top domains

See how Hanmi Pharm keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

hanmi.co.kr2.06

See more with Sales Intelligence

Hanmi Pharm top competitors by domain

Top similar sites in June 2026, ranked by their affinity

nippon-shinyaku.co.jpCompany NameNIPPON SHINYAKUEmployees1001 - 5000HQJapan, KyotoAnnual revenue> $1BTotal visits130.9KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Hanmi Pharm

These are the website technologies, by industry, used by Hanmi Pharm top domains

Social (3)

Instagram

Advertising (2)

DoubleClick

Conversion & Analytics (2)

Google Analytics

Email Services (2)

G Suite

More Technologies

6

See all

News & Signals from Hanmi Pharm

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHanmi Signs Exclusive Partnership partnered with Organon group on May 21st '26.Hanmi Pharmaceutical partners with Organon to export combination therapies to Southeast Asia.

NewsRudacure partners with Hanmi Signs Exclusive Partnership.[Bio CEO Interview] RudaCure CEO Yongho Kim pursues active joint research with Hanlim Pharmaceutical, including RCI001 Phase 1 clinical trials, to overcome the limitations of bio-ventures

NewsMerck partners with Hanmi Signs Exclusive Partnership.Merck (NYSE: MRK ) inks an agreement with South Korea's Hanmi Pharmaceutical securing exclusive global rights to the latter's efinopegdutide (formerly HM12525A), a once-weekly glucagon-like peptide-1/glucagon receptor dual agonist, for the potential treatment of nonalcoholic steatohepatitis (NASH).